Survodutide (BI 456906) is a synthetic acylated dual Glucagon/GLP-1 receptor agonist engineered for prolonged half-life, widely researched in hepatic lipid oxidation, MASH/fibrosis models, and energy expenditure.
Scientific Profile & Research Key Points: Survodutide
Survodutide (BI 456906) is a synthetic acylated dual Glucagon/GLP-1 receptor agonist engineered for prolonged half-life, widely researched in hepatic lipid oxidation, MASH/fibrosis models, and energy expenditure.
Active Batch Release Specifications (Lot SL-2026-160)
Analytical release verification for current Survodutide (5 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-160 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water or sterile neutral PBS (pH 7.4)
Temperature & Stability
Store lyophilized at -20°C; refrigerate reconstituted solution at 2°C–8°C.
Survodutide — Technical Questions & Answers
What is the molar concentration when reconstituting Survodutide (5 mg) in 2.0 mL?
Reconstituting the full 5 mg vial of Survodutide (MW 4231.65 g/mol) in 2.0 mL of diluent produces a 2.50 mg/mL stock solution — equivalent to approximately 0.59 mM (591 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does Survodutide's counterion stoichiometry affect assay mass calculations?
Survodutide (CAS 2805997-46-8, formula C192H289N47O61) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify Survodutide Lot SL-2026-160 and what pathway does it target?
Lot SL-2026-160 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 4231.65 g/mol. In preclinical literature, Survodutide targets Dual Glucagon Receptor (GCGR) & GLP-1 Receptor (GLP-1R) Agonist (Zimmermann T. et al., Mol Metab (2022) — BI 456906 (Survodutide) dual GCGR/GLP-1R energy expenditure and hepatic lipid models (PMID: 36270611)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
SLU-PP-332: Synthetic Pan-ERR Agonist Chemistry, DMSO Solubility & Mitochondrial Biogenesis
Analytical profile of small-molecule pan-ERR agonist SLU-PP-332 (CAS 303760-60-3): nuclear receptor EC50 selectivity, mitochondrial respiration models, and DMSO stock preparation.
Cagrilintide vs Retatrutide: Amylin/Calcitonin Receptors vs Triple Incretin Agonism
Biochemical comparison of long-acting amylin analogue Cagrilintide (AM833) against triple incretin agonist Retatrutide and dual-pathway Cagrilintide + Semaglutide combinations.
Survodutide vs Mazdutide vs Retatrutide: Dual GLP-1/Glucagon and Triple Agonist Biochemistry
Comparative receptor pharmacology of Survodutide (BI 456906), Mazdutide (IBI362), and Retatrutide (LY3437943): GLP-1R/GCGR/GIPR potency ratios and stability.